PTC Therapeutics Beheer
Beheer criteriumcontroles 2/4
De CEO PTC Therapeutics is Matt Klein, benoemd in Mar2023, heeft een ambtstermijn van 1.67 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.94M, bestaande uit 8.4% salaris en 91.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.068% van de aandelen van het bedrijf, ter waarde $ 2.27M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.7 jaar en 9.4 jaar.
Belangrijke informatie
Matt Klein
Algemeen directeur
US$8.9m
Totale compensatie
| Percentage CEO-salaris | 8.4% |
| Dienstverband CEO | 1.7yrs |
| Eigendom CEO | 0.07% |
| Management gemiddelde ambtstermijn | 5.7yrs |
| Gemiddelde ambtstermijn bestuur | 9.4yrs |
Recente managementupdates
Recent updates
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Fly 29% But Investors Aren't Buying For Growth
Oct 09
PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value
Sep 12Little Excitement Around PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Revenues
Jun 28PTC Therapeutics: Riding The Regulatory Rollercoaster With Translarna
May 22Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%
May 22PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts
May 14PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Mar 03PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options
Feb 11An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued
Jun 23Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price
May 18An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued
Mar 02PTC pauses enrollment in mid-stage study for Huntington's disease candidate in U.S.
Oct 19PTC Therapeutics betas topline expectations, strengthens commercial portfolio
Aug 05PTC Therapeutics gene therapy Upstaza wins approval in EU for ultra-rare neuromuscular disorder
Jul 20PTC Therapeutics: DMD Trial News Unlikely To Restore Flagging Share Price
Jun 24Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$453m |
| Jun 30 2024 | n/a | n/a | -US$480m |
| Mar 31 2024 | n/a | n/a | -US$579m |
| Dec 31 2023 | US$9m | US$747k | -US$627m |
| Sep 30 2023 | n/a | n/a | -US$642m |
| Jun 30 2023 | n/a | n/a | -US$618m |
| Mar 31 2023 | n/a | n/a | -US$571m |
| Dec 31 2022 | US$5m | US$598k | -US$559m |
Compensatie versus markt: De totale vergoeding ($USD 8.94M ) Matt } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.56M ).
Compensatie versus inkomsten: De vergoeding van Matt is gestegen terwijl het bedrijf verliesgevend is.
CEO
Matt Klein (52 yo)
1.7yrs
Tenure
US$8,937,025
Compensatie
Dr. Matthew B. Klein, also known as Matt, M.D., MS, FACS, serves as Chief Executive Officer and Director of PTC Therapeutics, Inc. since March 24, 2023He served as an Independent Director at ClearPoint Neu...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 1.7yrs | US$8.94m | 0.068% $ 2.3m | |
| Co-Founder | 26.8yrs | US$5.66m | geen gegevens | |
| Co-Founder | 26.8yrs | US$511.98k | 0.016% $ 533.8k | |
| Chief Financial Officer | 1.3yrs | US$3.01m | 0.015% $ 515.8k | |
| Executive VP & Chief Legal Officer | 12.7yrs | US$2.19m | 0.063% $ 2.1m | |
| Chief Business Officer | 9.6yrs | US$2.41m | 0.026% $ 852.9k | |
| Executive VP & Chief Medical Officer | 4.5yrs | US$2.39m | 0.019% $ 642.8k | |
| Senior VP | 5.4yrs | US$1.70m | 0.022% $ 737.2k | |
| Chief Technical Operations Officer | 5.9yrs | US$2.67m | 0.054% $ 1.8m | |
| Senior VP & Chief Information Officer | less than a year | geen gegevens | geen gegevens | |
| Investor Relations Officer | no data | geen gegevens | geen gegevens | |
| Vice President of Corporate Communications | no data | geen gegevens | geen gegevens |
5.7yrs
Gemiddelde duur
57yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van PTCT is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.7 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 1.7yrs | US$8.94m | 0.068% $ 2.3m | |
| Co-Founder | 1.7yrs | US$5.66m | geen gegevens | |
| Co-Founder | 26.8yrs | US$511.98k | 0.016% $ 533.8k | |
| Independent Chairman of the Board | 23.3yrs | US$816.96k | 1.95% $ 64.9m | |
| Independent Director | 18.9yrs | US$438.98k | 0.014% $ 453.8k | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 5.9yrs | US$441.98k | 0.0093% $ 311.4k | |
| Member of Scientific Advisory Board | 21yrs | geen gegevens | geen gegevens | |
| Independent Director | 9.4yrs | US$426.98k | 0.014% $ 453.8k | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 5.9yrs | US$421.98k | 0.0076% $ 253.7k |
9.4yrs
Gemiddelde duur
64yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van PTCT wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.4 jaar).